Condition
Post Polycythemia Vera Myelofibrosis
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
100.0%
3 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results0
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Terminated3
Clinical Trials (3)
Showing 3 of 3 trials
NCT04551066Phase 3Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551053Phase 3Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT01790295Phase 2Terminated
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Showing all 3 trials